Treprostinil signals via the IP or EP<sub>2</sub> receptor to inhibit dynamin-related protein (DRP1) and promote mitochondrial elongation in pulmonary arterial smooth muscle cells (PASMCs) from patients with pulmonary arterial hypertension (PAH).

**Author Block:** J. Abu-Hanna<sup>1</sup>, J. Taanman<sup>2</sup>, D. Abraham<sup>3</sup>, L. Clapp<sup>1</sup>.<sup>1</sup>Cardiovascular Physiology and Pharmacology, University College London, London, United Kingdom, <sup>2</sup>Clinical Neuroscience, University College London, London, United Kingdom, <sup>3</sup>Inflammation, University College London, London, United Kingdom,

**Abstract:**

**Introduction.** Prostacyclin analogues, such as treprostinil, are used clinically in the treatment of pulmonary arterial hypertension (PAH), a rare, progressive, life-threatening cardiopulmonary disorder (1). Central to the pathogenesis of PAH is the proliferation of pulmonary arterial smooth muscle cells (PASMCs) within the medial layers of small pulmonary arteries (1). Increased PASMC proliferation is associated with excessive mitochondrial fragmentation due to increased expression and activity of DRP1, a key effector of mitochondrial fragmentation (2). We sought to elucidate whether treprostinil acting on the IP or EP<sub>2</sub> prostanoid receptors inhibits DRP1 to promote mitochondrial fusion and elongation in PASMCs derived from patients with PAH.

**Method.** PASMCs were cultured with treprostinil (100 nM) for 3 hours alone or with either the IP receptor antagonist RO1138452 (1 μM), the EP<sub>2</sub> receptor antagonist PF04418948 (1 μM) receptor antagonist, a combination of both antagonists or the PKA inhibitor H-89. PASMCs were also treated with either the IP receptor agonist MRE-269 (100 nM) or the EP<sub>2</sub> receptor agonist butaprost (100 nM). Inhibitory DRP1 phosphorylation on serine 637 (pDRP1<sub>S637</sub>) was determined by western blotting. Live-cell imaging with MitoTracker Red CM-H2Xros was used to assess mitochondrial morphology.

**Results.** Low levels of pDRP1<sub>S637</sub> were observed in untreated PASMCs, while treprostinil markedly increased the levels of pDRP1<sub>S637</sub> (n = 3; p < 0.05) and promoted mitochondrial fusion and elongation. Although, individually, RO1138452 and PF04418948 had no effect on treprostinil-induced DRP1 phosphorylation, together they significantly blocked treprostinil-induced phosphorylation of DRP1 (n = 3; p < 0.01). Treprostinil-induced DRP1 phosphorylation was also abolished by H-89. (n = 3; p < 0.0001). Moreover, butaprost and MRE-269 were also able to stimulate DRP1 phosphorylation in PASMCs.

**Conclusions.** IP or EP<sub>2</sub> receptor agonism leads to inhibitory DRP1 phosphorylation on serine 637 by
PKA to promote mitochondrial fusion and elongation in PASMCs. **References**


**Categories (Complete):** 3. CARDIOVASCULAR AND RESPIRATORY PHARMACOLOGY ; 2. MOLECULAR AND CELLULAR PHARMACOLOGY

**Keywords (Complete):** Pulmonary hypertension ; Mitochondria ; Prostacyclin

**Presentation (Complete):** Poster

**Additional Questions (Complete):**

* Do you agree to your abstract being published on the BPS website before the meeting?: No
* Do you agree to your abstract being published on the BPS website before the meeting?: No
* Do you agree to your abstract being published on the BPS website before the meeting?: No
* Do you agree to your abstract being published on the BPS website before the meeting?: No

* I confirm that at least one author will register in full to attend and present the work at the Conference.: True
* I confirm: The research conducted meets the above listed ethical requirements and received approval from the formal regulatory body.

**Status:** Finalized

***To log out, simply close your browser window. All information will be saved if you have hit the Continue button after each step.***

---

**British Pharmacological Society**

The Schild Plot

16 Angel Gate

City Road

London EC1V 2PT

UK

Tel: + 44 (0)20 7239 0171

---

**FOR TECHNICAL SUPPORT:**

+1-217-398-1792 (Monday through Friday 9:00 am-5:00 pm North American Standard Central Time)

or OASIS Helpdesk

---

[Leave cOASIS Feedback](#)

---

Powered by cOASIS, The Online Abstract Submission and Invitation System™

© 1996 - 2018 CTI Meeting Technology. All rights reserved.